{"prompt": "['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', '1.2', 'Schedule of Activities', 'Visit', 'Visit 1', 'Visit 2', 'Visit 3', 'Visit 4', 'Visit 5', 'Visit 6', 'Screening', 'Baselinea', 'Week 2', 'Week 4', 'Week 8', 'Week 12/EOSb', 'Days', '-90 to -7', '1', '15 (4)', '29 ( 4)', '57 (7)', '85 ( 7)', 'Informed Consent/Assent', 'X', 'Demographics', 'X', 'Inclusion/Exclusion Criteria', 'X', 'Xc', 'Medical History', 'X', 'X (updated)', 'Concomitant Medications and Procedures/Therapies', 'X', 'X', 'X', 'X', 'X', 'X', 'Genetic testing/confirmation', 'X', 'Physical Examinationd', 'X', 'X (abbreviated)', 'X (abbreviated)', 'Vital Signs', 'X', 'X', 'Clinical Laboratory Tests', 'X', 'X', 'Urine Pregnancy Testing for WOCBP', 'X', 'X', 'X', 'X', 'Photography (Select Sites and Subjects having remote visits)', 'X', 'X', 'X', 'X', 'X', 'Clinical Evaluations (VIIS and IGA) (select Target for VIIS', 'Confirm', 'X', 'X', 'X', 'X', 'X', 'assessment)', '(prior to treatment application)', 'Record percent of BSA with CI in the VIIS Assessment Area and', 'X', 'Confirm', 'X', 'X', 'X', 'X', 'the Treatment Area', 'Age-appropriate Dermatology Life Quality Index and I-NRS', 'X', 'X', 'X', 'X', 'Local Skin Reactions', 'X', 'X', 'X', 'X', '(prior to treatment application)', 'Randomization', 'X', 'Visit', 'Visit 1', 'Visit 2', 'Visit 3', 'Visit 4', 'Visit 5', 'Visit 6', 'Screening', 'Baselinea', 'Week 2', 'Week 4', 'Week 8', 'Week 12/EOSb', '13']['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', 'Visit', 'Visit 1', 'Visit 2', 'Visit 3', 'Visit 4', 'Visit 5', 'Visit 6', 'Screening', 'Baselinea', 'Week 2', 'Week 4', 'Week 8', 'Week 12/EOSb', 'Days', '-90 to -7', '1', '15 ( 4)', '29 (4)', '57 ( 7)', '85 (7)', 'Days', '-90 to -7', '1', '15 ( 2)', '29 ( 2)', '57 ( 2)', '85 (3)', 'Study Treatment Accountability and dispensation to subject', 'X', 'X', 'X', 'X', 'X', 'Demonstrate how to apply the study treatment', 'X', 'X', 'X', 'X', 'Subject Diary: Dispense (D), Review (R), and/or Collect (C)', 'D', 'C+R+D', 'C+R+D', 'C+R+D', 'C+R', 'Instruct Subject to Continue Daily Treatment', 'X', 'X', 'X', 'X', 'Adverse Events', 'X', 'Xk', 'X', 'X', 'X', 'X\u00b9', 'Abbreviations: AE = adverse event; \u00df-hCG = beta human chorionic gonadotropin; BSA = body surface area; C = collect diary; CI = congenital ichthyosis; D = dispense diary; EOS = End of Study;', \"IGA = Investigator's Global Assessment; I-NRS = Itch-Numeric Rating Scale; R = review diary; VIIS = Visual Index for Ichthyosis Severity; WOCBP = women of childbearing potential.\", 'a Screening assessments (except for Genetic testing)may be performed up to 90 days prior to the Baseline Visit for those qualified subjects who are eligible to enroll in the study but require washout of', 'medications prior to enrolling into the Treatment Phase of the study. Genetic confirmation should be obtained prior to conducting additional eligibility assessments in the screening period. There is', 'no', 'window as it pertains to obtaining Genetic confirmation, it can be obtained at any time following consent and with no restriction until the Baseline Visit.', 'b Or early termination from the study.', 'c For those subjects who required genetic testing or a washout period related to exclusionary medications, reaffirm these subjects meet all protocol requirements at the Baseline Visit.', 'd Examination will include head and neck, dermatologic, cardiovascular, respiratory, gastrointestinal (abdomen), and gross motor and gait assessments. Abbreviated examination/ subject disposition', 'via directed query will be conducted at Visit 2 (Baseline) to identify any changes since the Screening Visit and Visit 6 (EOS) to assess changes throughout the study. Abnormalities at Visit 1', '(Screening) and Visit 2 (Baseline) will be recorded as medical history. Any new or worsening abnormality at all subsequent visits will be recorded as AEs.', 'e Assessments will be made after the subject has rested in a seated position for at least 5 minutes. Height and weight will also be measured at Visit 1 (Screening).', 'f Clinical laboratory tests (hematology, clinical chemistry, routine urinalysis) are provided in Table 7. Additional screening tests (as mentioned in Table 7) will be performed for Screening. Subjects', 'must be fasting (at least 8 hours) for Visit 1 (Screening) and, if possible, for Visit 6 (EOS). However, if a subject arrives at the clinic for Visit 6 (EOS) without fasting for at least 8 hours,', 'laboratory specimens may be collected as non-fasting, at the discretion of the Investigator and documented as such on the laboratory requisition form.', 'g', 'All urine pregnancy tests must have a minimum sensitivity of 25 mIU \u00df-hCG/mL.', 'h The term WOCBP is defined in Appendix 6.', 'i Subject will be assigned the next available (lowest) kit number in ascending order.', 'j Study staff will provide a Subject Instruction Sheet to the subject and parent/guardian (if applicable).', 'k During any washout and screening periods, any changes in the health of subjects should be recorded as changes in medical history unless an event occurred as a result of a study-related procedure', 'and was unanticipated. In such cases, the event should be recorded as an AE and reported to the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) as an \"unanticipated', 'problem\" in accordance with local procedures.', '1 Any treatment-related AEs that are ongoing at Visit 6 (EOS) must be followed until resolution or stabilization.', '14']\n\n###\n\n", "completion": "END"}